Wird geladen...
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4(+)) associates with lower overall and disease-free survival....
Gespeichert in:
| Veröffentlicht in: | Haematologica |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Ferrata Storti Foundation
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7049335/ https://ncbi.nlm.nih.gov/pubmed/31248974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.211490 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|